Preview

Вестник анестезиологии и реаниматологии

Расширенный поиск

АТИПИЧНЫЙ ГЕМОЛИТИКО-УРЕМИЧЕСКИЙ СИНДРОМ У ПАЦИЕНТКИ С МЕНОМЕТРОРРАГИЕЙ (клиническое наблюдение)

https://doi.org/10.21292/2078-5658-2016-13-3-63-70

Полный текст:

Аннотация

В статье приведено описание клинического наблюдения развития атипичного гемолитико-уремического синдрома у пациентки с менометроррагией, манифестировавшего на фоне маточного кровотечения и сопровождавшегося развитием острой почечной недостаточности.

 

Об авторах

А. В. Пырегов
ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» МЗ РФ, Москва
Россия
доктор медицинских наук, заведующий отделением анестезиологии-реанимации


Т. А. Федорова
ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» МЗ РФ, Москва
Россия
доктор медицинских наук, профессор, заведующая отделом трансфузиологии и экстракорпоральной гемокоррекции


А. Ю. Королев
ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» МЗ РФ, Москва
Россия
врач отделения анестезиологии-реанимации


К. И. Грищук
ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» МЗ РФ, Москва
Россия
врач отделения анестезиологии-реанимации


Список литературы

1. Клинические рекомендации по диагностике и лечению атипичного гемолитико-уремического синдрома // Нефрология и диализ. – 2015. – Т. 17, № 3. http://www.nephro.ru/content/files/242–264.pdf

2. Ariceta G., Besbas N., Johnson S. et al. European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome // Pediatr. Nephrol. – 2009. – Vol. 24. – P. 687–696.

3. Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders // Kidney Int. – 2006. – Vol. 70. – P. 423–431.

4. Campistol J. M., Arias M., Ariceta G. et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document // Nefrologia. – 2013. – Vol. 33. – P. 27–45.

5. Caprioli J., Noris M., Brioschi S. et al. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome // Blood. – 2006. – Vol. 108. – Р. 1267–1279.

6. Cataland S. R., Wu H. M. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies // Eur. J. Intern. Med. – 2013. – Vol. 24. – P. 486–491.

7. Cataland S. R., Yang S., Wu H. M. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies // Br. J. Haematol. – 2012. – Vol. 157. – P. 501–503.

8. Cataland S. R. Complement biomarkers and diagnosis of aHUS // Blood. – 2014. – Vol. 123, № 24. – URL: ncbi.nlm.nih.gov

9. Chan M. R., Thomas C. P., Torrealba J. R. et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient // Am. J. Kidney Dis. – 2009. – Vol. 53. – P. 321–326.

10. Constantinescu A. R., Bitzan M., Weiss L. S. et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course // Am. J. Kidney Dis. – 2004. – Vol. 43. – P. 976–982.

11. Coppo P., Schwarzinger M., Buffet M. et al. French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience // PLoS One. – 2010. – Vol. 5. – Р. e10208.

12. Donne R. L., Abbs I. Reccurence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor // Am. J. Kidney dis. – 2002. – URL: ncbi.nlm.nih.gov_ajkd.org

13. Dragon-Durey M. A., Sethi S. K., Bagga A. et al. Clinical features of anti-factor H autoantibody_associated hemolytic uremic syndrome // J. Am. Soc. Nephrol. – 2010. – Vol. 21. – P. 2180–2187.

14. Fremeaux-Bacchi V., Fakhouri F., Garnier A. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults // Clin. J. Am. Soc. Nephrol. – 2013. – Vol. 8. – P. 554–562.

15. Gasser C., Gautier E., Steck A. et al. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia // Schweiz Med. Wochenschr. – 1955. – Vol. 85. – P. 905–909.

16. Greenbaum L. A., Fila M., Tsimaratos M. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric atypical hemolytic uremic syndrome (aHUS) patients (pts). Presented at American Society of Nephrology (ASN) Kidney Week 2013, Atlanta, Ga., November 9, 2013.

17. Hofer J., Rosales A., Fischer C. et al. Extra-renal manifestations of complement-mediated thrombotic microangiopathies // Front. Pediatr. – 2014. – Vol. 2. – P. 97.

18. Kavanagh D., Goodship T. H. Atypical hemolytic uremic syndrome, genetic basis and clinical manifesatations // Hematology Am. Soc. Hemat. Educ. Program. – 2011. – P. 15–17. – URL: ncbi.nlm.nih.gov

19. Keating G. M. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome // Drugs. – 2013. – Vol. 73. – P. 2053–2066.

20. Keir L., Coward R. J. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy // Pediatr. Nephrol. – 2011. – Vol. 26. – P. 523–533.

21. Kremer Hovinga J. A., Vesely S. K., Terrell D. R. et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura // Blood. – 2010. – Vol. 115. – P. 1500–1511.

22. Legendre C. M., Licht C., Muus P. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome // N. Engl. J. Med. – 2013. – Vol. 368. – P. 2169–2181.

23. Loirat C., Freaux-Bacchi V. Atipical hemolytic-uremic syndrome // Orhanet. J. Rare Dis. – 2011. – Vol. 8. – P. 6–60.

24. Noris M., Caprioli J., Bresin E. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype // Clin. J. Am. Soc. Nephrol. – 2010. – Vol. 5. – P. 1844–1859.

25. Noris M., Galbusera M., Gastoldi S. et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy // Blood. – 2014. – Vol. 124. – P. 1715–1726.

26. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1676–1687.

27. Noris M., Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome // Nat. Rev. Nephrol. – 2014. – Vol. 10. – P. 174–180.

28. Pourrat O., Coudroy F. P. Differentiation between severe HELLP syndrome and trombotic microangiopathy, trombotic thrombocytopenic purpura and other imitators // European Journal of Obstetrics & Gynecology and Reproductive Biology. – 2015. – Vol. 189. – P. 68–72.

29. Rafiq A. Atypical hemolytic-uremic syndrome // Am. J. Case Rep. – 2015. – Vol. 16. – P. 109–114.

30. Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? // Pediatr. Nephrol. – 2014. – Vol. 29. – P. 329–332.

31. Sanches-Corral P., Melgosa M. Advanced in understanding aetiogy of atupical hemolytic uraemic syndrome // Br. J. Haemotol. – 2010. – Vol. 150. – P. 529–542.

32. Scully M., Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome // Br. J. Haematol. – 2014. – Vol. 164. – P. 759–766.

33. Sellier-Leclerc A. L., Fremeaux-Bacchi V., Dragon-Durey M. A. et al. French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome // J. Am. Soc. Nephrol. – 2007. – Vol. 18. – P. 2392–2400.

34. Shrivastava M. Early diagnosis and management of postpartum hemolytic uremic syndrome with plasma exchange // Transfus. Apheresis Sci. – 2011. – Vol. 44. – P. 257–262.

35. Thompson R. A., Winterborn M. H. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin // Clin. Exp. Immunol. – 1981. – Vol. 46. – P. 110–119.

36. Warwicker P., Goodship T. H., Donne R. L. et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome // Kidney Int. – 1998. – Vol. 53. – P. 836–844.

37. Wong E. K., Goodship T. H., Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS) // Mol. Immunol. – 2013. – Vol. 56. – P. 199–212.

38. Zuber J., Fakhouri F., Roumenina L. T. et al. French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies // Nat. Rev. Nephrol. – 2012. – Vol. 8. – P. 643–657.

39. Zuber J., Le Quintrec M., Morris H. et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation // Transplant Rev. (Orlando). – 2013. – Vol. 27. – P. 117–125.


Для цитирования:


Пырегов А.В., Федорова Т.А., Королев А.Ю., Грищук К.И. АТИПИЧНЫЙ ГЕМОЛИТИКО-УРЕМИЧЕСКИЙ СИНДРОМ У ПАЦИЕНТКИ С МЕНОМЕТРОРРАГИЕЙ (клиническое наблюдение). Вестник анестезиологии и реаниматологии. 2016;13(3):63-70. https://doi.org/10.21292/2078-5658-2016-13-3-63-70

For citation:


Pyregov A.V., Fedorova T.A., Korolev A.Y., Grischuk K.I. ATYPICAL HEMOLYTIC-UREMIC SYNDROME IN THE FEMALE PATIENT WITH CONCURRENT MENOMETRORRHAGIA (clinical case). Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2016;13(3):63-70. (In Russ.) https://doi.org/10.21292/2078-5658-2016-13-3-63-70

Просмотров: 105


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2078-5658 (Print)
ISSN 2541-8653 (Online)